InnoCare (诺诚健华) IPO: Momentum Matters but Mind the Limited Upside
InnoCare launched book building to raise up to USD 288 million to list in Hong Kong. In our previous notes, we have covered the company’s key...
419 Views
InnoCare (诺诚健华) Pre-IPO: PHIP and Valuation Update
InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company...
501 Views
InnoCare (诺诚健华) Pre-IPO: Thoughts on Valuation
InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company...
501 Views
Ascentage Pharma (亚盛医药) IPO: Some Issues with Banker Forecasts
Ascentage Pharma is pre-marketing the USD 200 - 300 million IPO to list in Hong Kong. In our previous insight, we highlight the company's key...
659 Views
Greater Bay Area Initiative - Viablity & Investor Implications, Part II
Last week in Part I we discussed what the GBA Initiative is. The importance of the GBA Initiative cannot be overstated. It is critical to the...
507 Views